iabetes mellitus affects about 7% of the populations of Canada and the United States -some 23 million people -and accounts for direct annual health care costs of about $105 billion.
are all potential barriers to aggressive management. Efforts to improve patients' self-management are thought to be central to improving diabetes management. [11] [12] [13] The most innovative and effective self-management interventions may be those that target the main provider and the patient as a unit, ideally producing a motivated patient who is willing to take charge of his or her care, with the primary care provider as a resource coach and triage to consultation services as needed. [14] [15] [16] [17] [18] All major Western health care systems are now advocating the expanded use of electronic medical records to improve the legibility, portability and storage of records and to improve the quality and cost-effectiveness of patient care. 19, 20 However, electronic medical records typically provide little decision support for patient management. Computerized decision-support systems integrated with the electronic medical record may improve prescribing and quality of care through the provision of patient-specific summaries and recommendations that are seamlessly integrated into the practice workflow. 14, 21, 22 The limited amount of high-quality research available suggests that computerized decision-support systems can change provider behaviour. However, there have been too few randomized trials to confirm that they can reliably improve patient outcomes. 23 Given the major expense of electronic medical records and computerized decision support, the effectiveness and cost-effectiveness of such systems is a major information gap.
Because of the high prevalence of diabetes, its significant morbidity and the multiple targets for therapy, both patients and providers are likely to benefit from an advanced, diabetesspecific computerized decision-support system. Our objective was to rigorously evaluate whether such a system, shared between patient and primary care provider, could improve the quality of diabetes management in primary care. The specific hypothesis was that patients in the intervention group, who had electronic and paper access to an individual diabetes tracker (with data related to recent monitoring and results and targets for 13 risk factors) and whose information was shared with their primary care providers, would have improved quality of diabetes care.
Methods

Participants and procedures
The Computerization of Medical Practices for the Enhancement of Therapeutic Effectiveness (COMPETE) II study was a pragmatic randomized trial of a complex intervention that was conducted in the province of Ontario, Canada, from late 2002 to the end of 2003. It was approved by the 3 presiding research ethics boards: St. Joseph's Healthcare, Hamilton; the Sisters of Charity, Ottawa; and Group Health Centre -Sault Area Hospital, Sault Ste. Marie.
We recruited community-based primary care providers across Ontario who were already using electronic medical records in their practices. Once the providers had signed consent, they identified from their rosters patients 18 years or older with a diagnosis of type 2 diabetes who were fluent in English and were able to understand the study description. From this list, we randomly selected the patients who would be approached for recruitment, and the providers sent invitations to their respective patients by mail. The randomization process used allocation concealment and central computer generation of group assignment, and it was stratified by provider and in blocks of 6. Participating patients and primary care providers then completed baseline questionnaires. We instructed patients in the intervention group to visit their respective local laboratories for a predetermined set of relevant blood tests and then to make an appointment with their respective family physicians for a week later. Study follow-up was to be 6 months. The electronic tracker interfaced with the provider's electronic medical record 25 and with an automated telephone reminder system for the patient. In addition to giving patients Web-based access to the tracker, we mailed a colour-coded tracker page to each patient in the intervention group (4 times a year) and asked that this page be taken to physician appointments. For the telephone reminder system, intervention patients registered with a voice biometric and then received monthly reminders for medications and for laboratory and physician visits. The overall intent of the intervention was to re-engineer the flow of care, such that updated tracker information and the most recent laboratory results were available to both provider and patient at the time of the patient's visit. Patients in the control group continued receiving usual care from their respective primary care providers.
Outcome measures
The primary outcome measure was based on improvement of process. We calculated this outcome as the difference between the intervention and control groups in terms of mean change for individual patients in a composite score of process quality for 6 months after randomization relative to baseline. The process composite score represented the sum of the quality of monitoring of each of the relevant variables (glycated hemoglobin, blood pressure, LDL cholesterol, body mass index [BMI], albuminuria, foot check, smoking and physical activity) compared with their respective targets (see Table 1 ). We modelled these recommendations on the guidelines of the Can adian Diabetes Association 7 and the American Diabetes Association. 24 If we could not find any evidence of a process (e.g., checking feet), we assumed that it had not happened. Secondary outcomes included the 8-item composite for clinical marker outcomes (Table 1) , a subset designated as the "ABC composite" ("A 1C " or glycated hemoglobin, blood pressure and cholesterol [LDL] ), evaluations of the tracker system and its effect on perceived usefulness, continuity of care 26 and quality of life (using the SF-12 questionnaire 27 for general quality of life and the Diabetes-39 questionnaire 28, 29 for diabetes-related quality of life). Both process and clinical composites were evaluated "harshly," such that worsening of a variable counted against improvements in other variables. We collected most of the data for the primary outcome by chart review, with other outcomes reflecting a combination of chart review and telephone questionnaires. Participants' views on the automated telephone reminder system 30 and data on the estimated cost-effectiveness of the intervention have been published elsewhere or are in preparation for publication in separate manuscripts.
Data analysis
Statisticians blinded to treatment allocation performed the data analysis. We accounted for all patients who underwent randomization in the groups to which they were assigned (i.e., intention-to-treat analysis). The null hypothesis was that the
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• Unable to contact n = 13
• Did not meet inclusion criteria n = 5 • Declined to participate n = 392 • Did not reply n = 689 mean improvements in the process-ofcare score for the 2 populations (intervention and control) would be equal. Based on α = 0.05 and a 2-tailed test with 1:1 allocation, the study had 80% power to detect a minimal clinically important difference of 1, with a total sample of 284. The sample size was calculated using Power and Precision software (www .power -analysis .com). The unit of randomization was the patient, because patients were considered the main determinant of intervention success. We then adjusted the sample size for potential clustering of scores within a provider's practice, assuming an intraclass correlation of 0.08 based on preliminary results for a few practices. The required sample was 508 patients (254 per group).
We imputed missing data using multiple imputation methods. 31 We used t tests to assess the difference between groups in terms of change in the process composite score. We used the χ 2 statistic to assess the proportions of patients for whom the composite improved or worsened. We analyzed clinical outcomes in 2 ways: whether there was any change (scoring each variable that improved as +1, each variable that worsened as -1 and each variable with no change as 0) and whether the outcomes met the targets (which was more challenging). We report the results as estimates of effect, with corresponding 95% confidence intervals (CIs) and associated p values. Analyses using generalized estimating equations to adjust for any clustering by provider did not change the results. We did not specify the operational definitions of success for the composite outcomes in the study protocol, but we finalized these definitions before undertaking the data analysis. A study graph displaying the intervention components and outcome assessments is available in Appendix 4 (available at www .cmaj .ca /cgi /content /full /cmaj.081272 /DC2).
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Results
We recruited 46 providers (mean age (Table 2) .
Process composite score
At baseline, the process composite score for both groups was 5.19 ( 
Clinical outcomes
At baseline, certain individual risk factors were reasonably well controlled: glycated hemoglobin about 7%, mean blood pressure about 135/75 mm Hg and LDL cholesterol about 2.5 mmol/L (Table 4) . However, only 19 (7.5%) of the patients in the intervention group had all 3 of these risk factors on target. There was a statistically significant difference in the 2 "clinical improvement" composite scores (i.e., the 8-variable composite score and the 3-variable "ABC" composite score).
The intervention group had a better change score than the control group for both the 8-variable composite (difference 0.55, 95% CI 0.04 to 1.07, p = 0.036) and the ABC composite (0.34, 95% CI 0.04 to 0.65, p = 0.028). The intervention group had improvement in the number of clinical composite variables that were on target (mean difference 0.16 relative to the control group); however, this difference was not statistically significant (p = 0.26). In the analysis of the ABC composite, the intervention group had a greater mean increase in the number of variables on target (0.19, 95% CI 0.004 to 0.38, p = 0.049). There were also statistically significant improvements in actual blood 
Research
Other outcomes
By the end of the study, patients in the intervention group were more optimistic than those in the control group in terms of their daily productivity and ease of management of their diabetes, their relationship with their respective primary care providers and the quality of their diabetes care. One hundred and ninety-two (75.9%) of the intervention patients were as satisfied or more satisfied with their care since starting to use the tracker system. There were no statistically significant changes in quality-of-life measures (SF-12 and Diabetes-39) or continuity of care, 33 despite positive trends. Note: ABC composite = composite of "A 1c " (glycated hemoglobin), blood pressure and LDL cholesterol; BMI = body mass index; CI = confidence interval; IQR = interquartile range; LDL = low-density lipoprotein; SD = standard deviation. *Differences are based on multiple imputation (may differ slightly from raw results). †Potential range for change in clinical composite score: -8 to +8. ‡For these 2 rows, data represent the change for each group over the study period (difference between "before" and "after"). §Range of scores for on-target clinical composite: 0 to 8 (blood pressure counted as 1 variable). **p = 0.036. † †**p = 0.049. ‡ ‡p = 0.029. § §p = 0.028. ***p = 0.049. † † †Both systolic and diastolic blood pressure had to be on target.
In providing their feedback, many primary care providers noted that the technical difficulties with the electronic decisionsupport tool had a negative effect on the perceived usefulness of the intervention. Despite this reservation, 48% (16/33) felt that their knowledge of diabetes targets had improved, 33% (11/33) felt that patients' adherence with appointments had improved, and 36% (12/33) felt that patients' access to high-quality diabetes care had improved (as opposed to no change).
Both patients and providers identified the main technical difficulty as lack of reliable access to the Web-based version of the diabetes tracker, which was attributed to suboptimal provincial health infrastructure. In addition, the inability to completely integrate the tracker's decision-support system with each of the 5 different types of electronic medical records, which would have allowed automated updating between the patient's medical record and the tracker system, meant that monitoring data had to be entered twice to keep both systems current. Lower-priority items mentioned by participants included the need for passwords, which were frequently misplaced by patients, and the feeling that nightly updating of intervention patients' tracker variables was not sufficiently timely.
Interpretation
E-health trials and their intervention arms represent a complex form of research -complex to develop, to implement and to evaluate. 34 Despite the technical challenges for both patients and primary care providers in this study, we have demonstrated that the care of a complex chronic disease can be improved with electronic tracking and decision support shared by providers and patients. Unlike the current trial, previous trials have been conducted in institutional settings, where information technology support is continuously and readily available, and have involved in-house electronic decision-support systems typically developed often over a period of decades. 35 Key elements of our intervention included its simultaneous focus on both providers and patients, multiple communication approaches (electronic, telephone and paper) and point-of-care multifactorial computerized monitoring and decision support.
However, the changes in outcomes that we observed were modest, as has been found in other interventions for the management of chronic disease. Several explanations are plausible. First, management of complex chronic diseases is especially difficult in the community, where the intense and frequent reminders, follow-up and support that may be required for important change are not generally available. Second, trials such as these frequently require pretesting and refinement to prepare the research setting, intervention, methods and outcomes of interest. 35 Third, we and others have found that computerized decision-support interventions, even those limited to prescribing, vary greatly in their characteristics or features. 36 Without better descriptions, it has been impossible to evaluate which features predict success and which predict failure, so that the effectiveness of the intervention can be improved. Fourth, the technical issues preventing instant access to necessary monitoring and advice are an underrecognized source of failure of computerized decision-support systems. Canadian e-health regulators and payers do not require standards for data extraction from the country's multiple electronic medical records; this lack of standards has led to expensive integration challenges and has inhibited rapid access to data by providers and patients. In addition, the failure by health jurisdictions to provide fast, reliable and secure Internet communication is a fundamental barrier to e-health progress.
The limitations of our research also include the relatively short follow-up time (6 months) and the resultant use of surrogate outcomes. For example, although process outcomes are often used for short-term trials, the optimal timing of process (checking a vascular risk factor, for example) has not been rigorously studied. 37 In addition, short-term follow-up led to a paradoxical situation in which the process improved markedly, only to reduce or minimally improve the overall mean score for clinical targets. Some of this is likely the result of newly identifying patients with poorer control, a worthwhile outcome in itself. Finally, although use of an intervention that targets multiple risk factors has been shown to significantly reduce vascular, renal, eye and neuropathy events, 8 it is not clear which of the clinical markers it is most important to target through behavioural or medication interventions.
Although we have demonstrated that individualized, evidence-based computerized decision support holds some promise for improving clinical care, there is as yet no compelling evidence of an important effect on major patient morbidity (e.g., cardiovascular and renal events). Providers who are not participating in research on these systems are correct to proceed cautiously and to be skeptical of current claims of improved efficiency, in terms of both time and money. The policy implications of this research are more immediate. There is an urgent need to improve the management of chronic diseases such as diabetes, and there is evidence that small changes in each of several risk factors can cumulatively have major clinical impact. Multiple types of electronic assistance, from simple archiving of the information in patient charts to the provision of specific, individual, real-time advice, have been proposed. Very little research on these topics exists in Canada, despite millions of patients with diabetes, vascular disease and other chronic diseases. We urgently require that the degree of policy rigour that has been applied to drugs be applied to broader e-health interventions for the management of chronic disease, to understand where electronic decision support is most likely to be cost-effective. A cost-effectiveness analysis of this trial is now under way.
